Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Wnt family member 9A (WNT9A), previously known as WNT14, is a secreted signaling glycoprotein and a member of the Wnt family, which consists of proteins involved in crucial developmental and homeostatic processes. WNT9A binds to Frizzled-family G protein–coupled receptors on the cell surface to activate the canonical Wnt/β-catenin signaling pathway, regulating gene expression patterns involved in cell fate, proliferation, and differentiation. It is essential for normal progression of embryonic bone and joint development, particularly in chondrocyte maturation and synovial joint formation. WNT9A is expressed in both normal and cancerous tissues, and its dysregulation has been associated with developmental disorders, fibrosis, and cancer.
Inhibition or modulation of Wnt ligand–receptor interaction (for Wnt pathway inhibitors, not WNT9A-specific); Blockade of Wnt/β-catenin signaling cascade (general for Wnt pathway, e.g., by targeting Porcupine [PORCN], Frizzled, or other Wnt pathway elements)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Wnt family member 9A (WNT9A).